Research map: Olverembatinib plus immunotherapy versus olverembatinib plus allogeneic hematopoietic cell transplantation in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

Back to the article

Papers in this map

  1. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology · Lan‐Ping Xu · 2018 · 301 citations · Cited by this paper
  2. Treatment of adult acute lymphoblastic leukemia—a therapeutic revolution in the making · Hagop M. Kantarjian · 2026 · Cites this paper
  3. Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients · 2026 · Related
  4. Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group · Thomas Burmeister · 2008 · 174 citations · Cited by this paper
  5. Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma · 2026 · Related
  6. Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL · Robin Foà · 2023 · 167 citations · Cited by this paper
  7. Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study · 2026 · Related
  8. Management of ALL in adults: 2024 ELN recommendations from a European expert panel · Nicola Gökbuget · 2024 · 140 citations · Cited by this paper
  9. Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study · 2026 · Related
  10. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia · Elias Jabbour · 2024 · 125 citations · Cited by this paper
  11. Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial · 2026 · Related
  12. Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL · Hagop M. Kantarjian · 2024 · 89 citations · Cited by this paper
  13. Preclinical and clinical efficacy of the HDAC6 inhibitor ricolinostat in combination with BCR pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia · 2026 · Related
  14. Efficacy and Toxicity of Frontline Ponatinib Plus Blinatumomab for Adult Ph+ ALL Patients of All Ages. Intermediate Analysis of the Gimema ALL2820 · Sabina Chiaretti · 2024 · 33 citations · Cited by this paper
  15. Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine · 2026 · Related
  16. Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib · Elias Joseph Jabbour · 2024 · 32 citations · Cited by this paper
  17. Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma · 2026 · Related
  18. Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab · Nicholas James Short · 2025 · 25 citations · Cited by this paper
  19. Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin · 2026 · Related
  20. First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients · Sabina Chiaretti · 2025 · 14 citations · Cited by this paper
  21. Dasatinib plus prednisone as induction and consolidation for adults with Ph‐positive acute lymphoblastic leukaemia: A single‐arm, multicentre, phase 2 trial · Mixue Xie · 2023 · 10 citations · Cited by this paper
  22. Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial · Xiaoyuan Gong · 2025 · 9 citations · Cited by this paper
  23. Olverembatinib Plus Low-Intensive Regimen in Frontline Therapy for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia： a Case Series from a Single Center · Yinjun Lou · 2022 · 5 citations · Cited by this paper

Source: OpenAlex (CC0)